Investors have been left with mixed emotions regarding the stock price performance over the year, as it’s been a mixed bag. This year’s metric has recorded a Price increase of 1.41%. However, over the past six months, we’ve seen a stronger performance of -42.09%. The price of LCTX leaped by -26.52% over the last 30 days. And in the last five days, it has fallen by -2.00%.
In terms of market performance, Lineage Cell Therapeutics Inc had a fairly uneven. The highest value for the stock in the past year was $1.61 on 03/28/24, and the lowest value was recorded at $0.48 on 03/19/25.
52-week price history of LCTX Stock
Analyzing a stock’s 52-week high and low prices can offer important information about its present condition and future outlook. Lineage Cell Therapeutics Inc’s current trading price is -68.35% away from its 52-week high, while its distance from the 52-week low is 7.06%. The stock’s price range during this period has varied between$0.48 and $1.61. The Lineage Cell Therapeutics Inc’s shares, which operate in the Healthcare, saw a trading volume of around 0.81 million for the day, a figure considerably lower than their average daily volume of 1.77 million over last three months.
Market Capitalization vs. Financial Performance: A Comparative Study
Lineage Cell Therapeutics Inc (LCTX) has experienced a quarterly rise of 2.56% in its revenues when compared to the same period in the previous year. Presently, the company has a total market capitalization of 116.37M and boasts a workforce of 77 employees.
Combining Moving Average and Trading Volume Data for Better Market Insight
Based on Barchart.com data, the company’s moving average over the 100-day period was 0.6346, with a change in price of -0.3415. Similarly, Lineage Cell Therapeutics Inc recorded 2,042,193 in trading volume during the last 100 days, posting a change of -39.89%.
LCTX’s Debt-to-Equity Ratio Cause for Concern? An In-Depth Look
The debt-to-equity (D/E) ratio is a significant metric that provides insights into a company’s financial state and market presence. By dividing a company’s current liabilities by its shareholders’ equity, the D/E ratio depicts the extent of debt used by a company to fund its assets relative to the value of its shareholders’ equity. At the time of writing, the total D/E ratio for LCTX stands at 0.03. Similarly, the long-term debt-to-equity ratio is also 0.02.
LCTX Stock Stochastic Average
Lineage Cell Therapeutics Inc’s raw stochastic average for the past 50 days is presently 14.09%, as of today. This marks a decrease from the raw stochastic average of the last 20 days, which was 18.05%. Additionally, the company’s Stochastic %K and %D values for the past 20 days were 11.67% and 6.91%, respectively.
